Completed

1

14

RoW

KF-0210 tablets, 120 mg, KF-0210-0, KF-0210 tablets, 240 mg, KF-0210 tablets, 450 mg, KF-0210 tablets, 600 mg, KF-0210 (dosage RP2D-2) + Atezolizumab, Tecentriq, KF-0210 (dosage RP2D-1) + Atezolizumab, KF-0210 (dosage RP2D) + Atezolizumab

Keythera Pharmaceuticals (Australia) Pty Ltd

Advanced Solid Tumor, Colorectal Cancer, Lung Cancer, Squamous Cell Carcinoma of the Esophagus, Gastric Cancer, Bladder Cancer

12/22

04/23